Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients by Eiichiro Kanda et al.
Kanda et al. BMC Nephrology 2012, 13:122
http://www.biomedcentral.com/1471-2369/13/122RESEARCH ARTICLE Open AccessApplicability of fibroblast growth factor 23 for
evaluation of risk of vertebral fracture and
chronic kidney disease-mineral bone disease in
elderly chronic kidney disease patients
Eiichiro Kanda1,2,3*, Masayuki Yoshida2 and Sei Sasaki3Abstract
Background: Elderly patients with chronic kidney disease (CKD) are usually at a high risk of fractures due to both
osteoporosis and CKD-mineral bone disease (MBD). A new marker is needed to prevent fractures and control
CKD-MBD from the early to advanced stages of CKD. In the early stage of CKD, fibroblast growth factor 23 (FGF23)
level increases before parathyroid hormone (PTH) and phosphate levels increase, and steadily increases with
the progression of kidney disease. It has been reported that FGF23 is related to the overall fracture risk.
We investigated the usefulness of FGF23 as a marker for evaluating the risk of vertebral fracture and CKD-MBD
in elderly CKD patients.
Methods: One hundred and five elderly predialysis CKD patients who had never been treated for osteoporosis
and had never used calcium supplements, vitamin D supplements, or phosphate binders were enrolled in this
cross-sectional study in Tokyo, Japan. We investigated the prevalence of vertebral fracture and measured serum
calcium, phosphate, 1,25(OH)2 vitamin D [1,25(OH)2D], intact PTH, FGF23, alkaline phosphatase, and urinary
N-terminal telopeptide levels. Then, we examined the relationship between the level of FGF23 and those of
bone-metabolism-related markers and identified markers associated with vertebral fractures in elderly CKD patients.
Results: The background features of the patients were as follows: female, 32.4%; diabetes mellitus, 39.0%; average
age (standard deviation), 73.2 (7.7) years; and estimated glomerular filtration rate (eGFR), 45.7 (24.1) ml/min/1.73 m2.
Adjusted multivariate regression analysis showed that the natural logarithm value of FGF23 level [ln(FGF23)] was
positively associated with body mass index (p= 0.002), serum phosphate level (p= 0.0001), and negatively with
eGFR (p= 0.0006). Multivariate logistic regression analysis showed that vertebral fracture was independently
associated with ln(FGF23) (adjusted odds ratio, 4.44; 95% confidence interval, 1.13-17.46). A
receiver-operating-characteristic curve of ln(FGF23) showed that the optimal cutoff level of FGF23 indicative of
vertebral fracture was 56.8 pg/ml (sensitivity, 0.82; specificity, 0.63).
Conclusions: FGF23 level was independently associated with the levels of bone-metabolism-related markers and
vertebral fracture. FGF23 is a new candidate marker for detecting abnormalities of bone metabolism and vertebral
fracture in elderly CKD patients.
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Elderly persons are at a high risk of osteoporotic fractures,
because of their decreased bone mineral density (BMD).
Vertebral fracture is most common [1,2]. There are several
studies showing an increased fracture risk among chronic
kidney disease (CKD) patients [3-6]. CKD patients tend to
show a lower BMD than the general population [7]. Kid-
ney dysfunction is associated with a more rapid decrease
in BMD over time [8]. These findings indicate that elderly
CKD patients are at a higher risk of fractures because of
both CKD and aging than the general population.
CKD affects bone metabolism with a decreased level
of the active form of vitamin D, namely, 1,25 dihydroxy
vitamin D [1,25(OH)2D], and an increased level of the
parathyroid hormone (PTH), resulting in CKD-mineral
bone disease (MBD) [9]. In CKD, fibroblast growth fac-
tor 23 (FGF23) level increases early before PTH and
phosphate levels increase, and steadily increases with the
progression of kidney disease [10]. The Swedish group
of the Population-based Osteoporotic Fractures in Men
(MrOS) study, a prospective study, showed that FGF-23
is directly associated with the overall fracture risk and
vertebral fracture risk in elderly males with an aver-
age estimated glomerular filtration rate (eGFR) of
72.0 ± 20.5 ml/min/1.73 m2 [11].
Pathological abnormalities of renal osteodystrophy
begin in the early stages of CKD [12]. A study on early
stage CKD showed that serum calcium and phosphate
levels are normal until the eGFR becomes lower than
40 ml/min/1.73 m2 [13]. Serum phosphate level is not
useful for monitoring CKD-MBD at an early stage of
CKD, because the changes in serum phosphate level
caused by therapy are usually small when the serum
phosphate level is within the normal range. We need a
new marker of CKD-MBD with higher sensitivity to ther-
apy effects and higher accuracy in identifying patients
at a high risk of clinical outcomes of CKD than serum
phosphate level at predialysis.
Elderly individuals with CKD often have high risks of
both osteoporosis and CKD-MBD. FGF23 level has a
potential for identifying early-stage CKD patients that
should be targeted for CKD-MBD therapy. For FGF23
level to be clinically useful, it should be demonstrated that
FGF23 is a risk factor for the clinical outcomes of CKD,
and the target FGF23 level for the prevention of such
clinical outcomes should be determined. In this study,
we investigated the prevalence of vertebral fracture that
occurred within five years in predialysis CKD patients and
whether FGF23 level is associated with vertebral fracture.
Methods
Study design and study population
This is a cross-sectional study of predialysis CKD
patients treated at Tokyo Kyosai Hospital, Tokyo, Japan,which was approved by the Ethics Committee of Tokyo
Kyosai Hospital. Patients were eligible for inclusion in the
sample for this study when they were at least 60 years of
age as of October 1st, 2010, diagnosed as having CKD on
the basis of the criteria of the Japanese Society of Nephrol-
ogy, had never been treated by dialysis or transplantation,
had never been treated for osteoporosis, and had never
used calcium supplements, vitamin D supplements, phos-
phate binders, steroids, or immunosuppressants [14]. All
the female patients were postmenopausal. Patients who
were treated for dementia, congestive heart failure, pul-
monary disease, liver disease, or cancer were excluded. We
treated CKD in accordance with the CKD practice guide-
line of the Japanese Society of Nephrology [14]. Body mass
index (BMI) was calculated using the following formula:
BMI ¼ weight kgð Þ=height mð Þ2 . eGFR was calculated indi-
vidually using the formula adopted by the Japanese Society
of Nephrology using serum creatinine level [14].Data
Patient demographics including age, gender, and history
of diabetes mellitus, as well as comorbid conditions,
were obtained from the medical records of the patients
treated at Tokyo Kyosai Hospital. Incident vertebral frac-
tures that occurred within five years, which were diag-
nosed by orthopedists on the basis of X-ray, computed
tomography, or magnetic resonance imaging findings,
were also obtained from medical records. Intact PTH
and 1,25(OH)2D levels were measured as CKD-MBD-
related markers. Urinary N-terminal telopeptide (urinary
NTX) and alkaline phosphatase (ALP) levels were mea-
sured as bone turnover markers [15-17]. Routine serum
biochemistry of phosphate, calcium, serum creatinine,
urinary creatinine, and intact PTH levels (1–84) was car-
ried out by standard methods at Tokyo Kyosai Hospital.
Intact PTH level was measured using an immunoassay
system (ARCHITECT PTH, Abbott Japan Co., Chiba,
Japan). 1,25(OH)2D, urinary NTX, and serum intact
FGF23 levels were measured by SRL Inc., Japan. 1,25
(OH)2D level was analyzed using a commercially avail-
able kit, (1,25(OH)2D RIA, TFB Co., Tokyo, Japan).
Serum intact FGF23 level was measured by enzyme-
linked immunosorbent assay (ELISA) with an intra-assay
coefficient of variation (CV) of 3.8% at a low standard
FGF23 level, an intra-assay CV of 2.4% at a high stand-
ard FGF23 level, and an intra-assay CV of 2.8% (Kainos
Laboratories International Co., Tokyo, Japan). Urinary
NTX level was also analyzed by ELISA (OSTEOMARK,
Inverness Medical Co., Chiba, Japan).Statistical analyses
Continuous variables for normal distribution were exam-
ined by the Kolmogorov-Smirnoff test. Normally distributed
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(SD); otherwise, mean, SD, median and interquartile range
(IQR) are presented here. For parameters not normally
distributed, natural logarithm values were considered in
tests that require normally distributed variables after the
tests of their normality: the natural logarithm values of
FGF23 level [ln(FGF23)] and PTH level [ln(iPTH)]. Inter-
group comparisons were performed using the chi-square
test, t-test, and Mann–Whitney U test as appropriate.
Pearson’s correlation coefficient, r, was used to assess
the relationship between ln(FGF23) and the levels of other
bone-metabolism-related markers. Multivariate linear re-
gression analysis was carried out to identify variables that
were independently associated with ln(FGF23) by includ-
ing factors that were previously selected on the basis of
Pearson’s correlation coefficient. Univariate logistic regres-
sion analysis was performed to identify variables that were
associated with vertebral fracture. Then, multivariate logis-
tic regression analysis was performed to identify variables
that were independently associated with vertebral fracture
by including factors that were previously selected on the
basis of the results of the univariate logistic regression
analysis. The values of odds ratio (OR) and 95% confi-
dence interval (CI) are summarized. The probability of
vertebral fracture occurring in each patient was predictedTable 1 Baseline characteristics of patients with vertebral fra
All
N (%) 105
Age (years) 73.2 (7.7)
Female (%) 34 (32.4)
Diabetes mellitus (%) 41 (39.0)
Height (cm) 159.5 (6.9)
Weight (kg) 61.3 (8.6)
BMI (kg/m2) 24.0 (2.5)
eGFR (ml/min/1.73 m2) 45.7 (24.1)
Calcium level (mmol/l) 2.4 (0.1)
Phosphate level (mmol/l) 1.1 (0.2)
Intact PTH level (ng/l) 143.6 (139.4)
96.2 (IQR, 65.8-154.4)
Ln(iPTH) 4.7 (0.7)
1,25(OH)2D level (pmol/l) 122.6 (54.6)
FGF23 level (pg/ml) 78.0 (101.7)
49.0 (IQR, 34.0-71.0)
Ln(FGF23) 4.0 (0.7)
ALP level (U/l) 227.0 (83.1)
Urinary NTX level (nmol.BCE/mmol.Cr) 35.8 (24.3)
Values are expressed as mean (SD). The levels of intact PTH and FGF23 are presente
groups by the chi-square test, t-test, or Mann–Whitney U test as appropriate.
Abbreviations: with-fracture group, group with vertebral fracture; without-fracture g
glomerular filtration rate; intact PTH intact parathyroid hormone; ln(iPTH) natural log
vitamin D; FGF23 fibroblast growth factor 23; ln(FGF23) natural logarithm value of fi
N-terminal telopeptide; SD standard deviation; IQR interquartile range.by calculation using a univariate logistic regression model
with ln(FGF23). A receiver-operating-characteristic (ROC)
curve was used to determine the optimal cutoff FGF23
level for determining the presence of vertebral fracture, at
which optimal sensitivity and specificity were achieved
[18]. The cutoff level was determined from the minimal
value of (1-sensitivity)2 + (1-specificity)2 and the Youden
index. We defined ln(FGF23) to be high on the basis of
the cutoff level determined from the previously obtained
ROC curve. The categorized values were treated as binary
numbers. We estimated the prevalence of vertebral frac-
ture and calculated the OR of a high ln(FGF23) with
respect to normal levels by univariate logistic regression
and multivariate logistic regression analyses including fac-
tors that were selected on the basis of the results of the
previously conducted univariate logistic regression ana-
lysis. These analyses were conducted using SAS, version
9.2 (SAS, Inc., Cary, North Carolina). Statistical signifi-
cance was defined as p<0.05.
Results
One hundred and five elderly CKD patients were
included in the sample for analysis. Patient demograph-
ics including biochemical data are shown in Table 1. The
causes of CKD were as follows: diabetic nephropathy,cture in comparison with those without the fracture
With-fracture group Without-fracture group p value
11 (10.5) 94 (89.5)
79.0 (6.6) 72.5 (7.5) 0.008
5 (45.5) 29 (30.9) 0.33
4 (36.4) 37 (39.4) 0.84
161.1 (3.7) 159.2 (7.2) 0.41
63.2 (2.5) 61.0 (9.2) 0.44
24.4 (1.5) 24.0 (2.6) 0.60
32.9 (18.8) 47.2 (24.3) 0.063
2.3 (0.2) 2.4 (0.1) 0.85






4.8 (0.5) 4.7 (0.7) 0.60






4.6 (0.8) 3.9 (0.7) 0.005
252.1 (103.5) 224.1 (80.5) 0.29
36.9 (27.3) 35.6 (24.1) 0.88
d with mean (SD), and median (IQR). The levels are compared between the
roup, group without vertebral fracture; BMI body mass index; eGFR estimated
arithm value of intact parathyroid hormone level; 1,25(OH)2D 1,25(OH)2
broblast growth factor 23 level; ALP alkaline phosphatase; urinary NTX urinary
Table 3 Vertebral fracture correlated with background










Age (per increase in 1 year) 1.13 (1.03-1.24) 1.13 (1.02-1.26)




BMI (per increase in 1) 1.07 (0.83-1.37)
eGFR (per increase in
1 ml/min/1.73 m2)
0.97 (0.95-1.00) 1.03 (0.98-1.08)
Calcium level
(per increase in 1 mmol/l)
0.63 (0.005-72.0)
Phosphate level
(per increase in 1 mmol/l)
1.38 (0.10-18.86)
Ln(iPTH) (per increase in 1) 1.38 (0.59-3.23)
1,25(OH)2D level
(per increase in 1 pmol/l)
0.98 (0.97-1.00)
Ln(FGF23) (per increase in 1) 2.70 (1.27-5.74) 4.44 (1.13-17.46)
ALP level (per increase in 1 U/l) 1.00 (0.99-1.01)
Urinary NTX level (per increase
in 1 nmol.BCE/mmol.Cr)
1.00 (0.98-1.03)
Multivariate logistic regression OR was determined from a logistic regression
model that includes age, eGFR, and ln(FGF23) as variables.
Abbreviations: OR odds ratio; CI confidence interval; BMI body mass index;
eGFR estimated glomerular filtration rate; ln(iPTH) natural logarithm value of
intact parathyroid hormone level; 1,25(OH)2D 1,25(OH)2 vitamin D; ln(FGF23)
natural logarithm value of fibroblast growth factor 23 level; ALP alkaline
phosphatase; urinary NTX urinary N-terminal telopeptide.
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ritis, 35.6%; and others, 8.1%. Eleven patients were diag-
nosed as having vertebral fracture (10.5%). Intact PTH
and FGF23 levels were log-normally distributed: mean
(SD) intact PTH level, 143.6 (139.4) ng/l with a median
of 96.2 (IQR, 65.8-154.4); FGF23 level, 78.0 (101.7) pg/ml
with a median of 49.0 (IQR, 34.0-71.0).
Groups with and without fractures were balanced
for gender, diabetes, BMI, eGFR, serum calcium level,
serum phosphate level, intact PTH level, ALP level, and
urinary NTX level. The average age of the with-fracture
group was higher than that of the without-fracture group.
The with-fracture group showed a lower 1,25(OH)2D level
and a higher FGF23 level than the without-fracture group.
FGF23 and markers of bone metabolism
There was a correlation between ln(FGF23) and the
levels of bone-metabolism-related markers (Table 2). Ln
(FGF23) was positively associated with age, BMI, serum
phosphate level, and ln(iPTH), and urinary NTX level,
and negatively with eGFR, serum calcium level, and 1,25
(OH)2D level. Multivariate regression analysis of the
variables age, BMI, eGFR, calcium level, phosphate level,
ln(iPTH), 1,25(OH)2D level, and urinary NTX level
showed that ln(FGF23) was independently associated
with BMI, eGFR, and serum phosphate level.
FGF23 and vertebral fracture
The associations between vertebral fracture and the
levels of bone-metabolism-related markers are shown in






r p β p
Age 0.22 0.026 −0.006 0.31
BMI 0.24 0.019 0.056 0.002
eGFR −0.73 0.0001 −0.012 0.0006
Calcium level −0.33 0.0006 −0.53 0.23
Phosphate level 0.48 0.0001 0.90 0.0001
Ln(iPTH) 0.68 0.0001 0.16 0.12
1,25(OH)2D level −0.63 0.0001 −0.0022 0.08
ALP level 0.19 0.06
Urinary NTX level 0.26 0.009 0.0014 0.47
Values are expressed as r (Pearson’s correlation coefficient), β (estimated
parameter), and p values.
Multiple regression analysis of age, eGFR, calcium level, phosphate level, ln
(iPTH), and 1,25(OH)2D level as variables.
Abbreviations: ln(FGF23) natural logarithm value of fibroblast growth factor 23
level; BMI body mass index; eGFR estimated glomerular filtration rate; ln(iPTH)
natural logarithm value of intact parathyroid hormone level; 1,25(OH)2D 1,25
(OH)2 vitamin D; FGF23 fibroblast growth factor 23; ALP alkaline phosphatase;
urinary NTX urinary N-terminal telopeptide.that vertebral fracture was associated with age, eGFR,
and ln(FGF23). The estimated probability obtained using
a univariate logistic model with ln(FGF23) was used to
assess the effect of FGF23 level on vertebral fracture
(Figure 1). The estimated probability of vertebral frac-
ture tended to increase with FGF23 level. A multi-
variate logistic regression model including age, eGFR,
and ln(FGF23) showed that ln(FGF23) was independ-
ently associated with vertebral fracture.
The ROC curve shows the accuracy of ln(FGF23) in
identifying patients at different prevalence rates of verte-
bral fracture examined in all the participants (Figure 2).
At the cutoff level, ln(FGF23) was 4.04 (FGF23
level = 56.8 pg/ml): sensitivity, 0.82; specificity, 0.63; area
under the curve (AUC), 0.787. Univariate and multi-
variate logistic regression analyses showed associations
between the likelihood of vertebral fracture and high
ln(FGF23): OR, 6.62 (CI, 1.63-26.84); OR adjusted for
age and eGFR, 7.91 (CI, 1.09-57.56).
Discussion
CKD and osteoporosis are common diseases associated
with aging, and the number of people with these
Figure 1 Predicted probability of detecting vertebral fracture increases with FGF23 level. A dot shows whether a patient has vertebral
fracture (predicted probability = 1) or not (predicted probability = 0). A line shows the predicted probability of detecting vertebral fracture in a
patient. The blue area is the 95% confidence interval. Abbreviations: estimated probability, estimated probability of occurrence of vertebral
fracture; ln(FGF23), natural logarithm value of fibroblast growth factor 23 level.
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ever, there are still many unresolved issues about these
diseases: the details about bone metabolism in patients
with these diseases and the identification of patients
with a high risk of fractures. Our findings are consistent
with previous reports that the FGF23 level is high in
CKD patients with decreased eGFR, increased PTH
level, and decreased 1,25(OH)2D level [19]. We found
that FGF23 level was independently associated with ver-
tebral fracture that occurred within five years in elderlyFigure 2 Receiver operating characteristic curve for ln(FGF23)
at optimal cutoff level for predicting vertebral fracture.
Abbreviations: ln(FGF23), natural logarithm value of fibroblast growth
factor 23 level.CKD patients. The MrOS study showed prospectively
that FGF23 level is related to fracture risk in elderly
CKD male patients [11]. In this study, no statistically
significant difference in the risk of vertebral fracture
was found between genders. These findings can be
extended to the association between FGF23 level and
vertebral fracture in both sexes with advanced CKD.
Moreover, we were able to determine the cutoff FGF23
level for identifying the patients with a high risk of ver-
tebral fracture.
Mutations of FGF23-related genes are associated with
several human skeletal disorders. It has been shown
that low FGF23 activity due to mutations in GALNT3,
FGF23, and Klotho leads to familial hyperphosphatemic
tumoral calcinosis, which is characterized by enhanced
renal tubular phosphate reabsorption and high serum
1,25(OH)2D level in hyperphosphatemia [20-22]. Some
types of rickets and osteomalacia such as X-linked hypo-
phosphatemic rickets/osteomalacia, hypophosphatemic
rickets/osteomalacia associated with McCune-Albright
syndrome/fibrous dysplasia, and tumor-induced rickets/
osteomalacia show hypophosphatemia and an increased
FGF23 level [23-27]. Overexpressed human FGF23
during osteoblast development in fetal rat calvaria cells
suppresses not only osteoblast differentiation but also
matrix mineralization independently of its systemic
effects on phosphate homeostasis in vitro [28]. A rickets
mouse model shows defective osteocyte maturation, an
increased FGF23 expression level, and pathological
changes in bone mineralization [29]. These clinical and
experimental findings suggest that an increased FGF23
level in CKD patients may affect the regulation of bone
formation and reabsorption. However, these diseases and
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humans or animals with normal kidney function. The
role of FGF23 in skeletal mineralization remains unclari-
fied in CKD patients. The high level of FGF23 in CKD
is considered to further increase as a compensatory
response to maintain phosphate balance because of sup-
pressed renal phosphate excretion or phosphate overload
[30,31]. It has been reported that high FGF23 levels are
associated with thin osteoids and a short osteoid matu-
ration time in children with renal failure on peritoneal
dialysis [32]. Although these findings are not fully
applicable to elderly CKD patients, this report suggests
that FGF23 indicates the skeletal mineralization status in
CKD patients. FGF23 could be a marker of CKD-MBD.
In this study, ROC showed that the cutoff FGF23 level
was 56.8 pg/ml. The adjusted logistic regression analysis
showed that FGF23 level was an independent factor
associated with the prevalence of vertebral fracture that
occurred within five years. As far as we researched, there
is only one report about the cutoff level for detecting the
risk of fractures. The MrOS study showed prospectively
that FGF23 levels higher than 55.7 pg/ml are associated
with an increased risk of hip and nonvertebral fractures
and that FGF23 levels higher than 57.4 pg/ml are asso-
ciated with an increased risk of vertebral fracture [11].
They used the same ELISA kit as in our study, and these
cutoff levels are similar. These two studies differed in
the population with regard to age, gender, GFR, and
location. Age is an independent risk factor for vertebral
fracture [1,2]. GFR is associated with BMD [7,8] and a
major predictor of FGF23 level variance in CKD patients
[33]. Although these findings indicate the importance of
FGF23 level for detecting CKD patients at a high risk of
fractures, they do not fully support the validity of these
cutoff levels among genreal CKD patients because of the
confounding effect of eGFR. The difference in FGF23
level between CKD populations has not been established
yet. To determine the cutoff FGF23 level for clinical
applications, larger population-based prospective studies
need to be carried out.
According to bone biopsy studies, pathological abnor-
malities in renal osteodystrophy begin in the early stages
of CKD [12]. However, the optimal management of
CKD-MBD including the monitoring of the levels of
markers and therapies initiated at the early stages of CKD
has not been established yet. Our study showed that
ln(FGF23) was independently positively associated with
CKD-MBD-related markers and negatively with eGFR. It
has been reported that increased FGF23 levels are as-
sociated with an increased risk of progressive CKD in-
dependently of normal serum phosphate level [34].
Moreover, an increased FGF23 level is more predictive of
CKD progression than serum phosphate level [34]. The
changes in serum phosphate level within the normalrange tend to not sensitively reflect CKD-MBD in early
stages of CKD. On the other hand, FGF23 and PTH
levels are often elevated in CKD, but it remains undeter-
mined which increases first and whether the pattern is
uniform across all CKD patients. According to the
Chronic Renal Insufficiency Cohort Study, FGF23 level
increases before PTH and phosphate levels increase in
CKD patients [10]. Therefore, FGF23 level can be one of
the candidate new markers, because it reflects the pro-
gression of CKD-MBD, can be easily followed up longi-
tudinally from the early stages of CKD, and can predict
outcomes. The AUC of our study was 0.787, which indi-
cates a moderate accuracy [18]. Although this accuracy
may not be very high for FGF23 level to be used as a
gold standard for identifying patients with a risk of ver-
tebral fracture, FGF23 level together with the levels
of other bone-metabolism-related markers and dual-
energy X-ray absorptiometry will be a more useful tool
than FGF23 level alone for evaluating CKD-MBD and
the risk for fractures and for deciding medications for
CKD patients to prevent fractures and progression of
CKD-MBD.
This study has several limitations. First, as with any
cross-sectional study, we were unable to examine the
longitudinal changes in laboratory findings over time.
Nonetheless, this study showed that FGF23 level is
independently associated with vertebral fractures that
already occurred. Second, in this study, we examined
105 patients. The statistical power of this study may not
be sufficient for detecting the relationship between frac-
tures and levels of markers. Third, geographical and
selection biases may have been included in this study.
Fourth, BMD, bone turnover, and mineralization were
not measured by an accurate method, such as bone
biopsy, in this population. We were unable to evaluate
the relationship between FGF23 level and BMD. Fifth,
we did not evaluate the medicines used and their effects
on the prognosis of kidney function. Sixth, 25-hydroxy
vitamin D level was not measured in this study. We were
unable to evaluate the CKD patients’ status of vitamin D
metabolism. Seventh, only postmenopausal females were
enrolled in this study. Thus, we were unable to deter-
mine the role of FGF23 in menopausal or premeno-
pausal females.
Conclusions
For elderly CKD patients, age-related bone diseases and
CKD-MBD are significant issues, because such diseases
strongly affect their quality of life and mortality. How-
ever, there has been no strong evidence that can fully
establish indicators that can help guide therapies for
bone diseases. We found that the level of FGF23 was
associated with those of CKD-MBD-related markers and
vertebral fracture in elderly CKD patients. FGF23 level
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abnormalities of bone metabolism and vertebral frac-
tures from the early to advanced stages of CKD.
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